Skip to content

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Careers
Contact

Menu

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Careers
Contact

Month: October 2022

Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit

Portfolio News / By Karina Tin

October 26, 2022

eFFECTOR Completes Enrollment in Second of Three Cohorts of Phase 1B Clinical Trial of Zotaifin for the Treatment of Covid-19

Portfolio News / By Karina Tin

October 26, 2022

NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621

Portfolio News / By Karina Tin

October 17, 2022

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Portfolio News / By Karina Tin

October 6, 2022

Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update

Portfolio News / By Karina Tin

October 6, 2022

Search for:

Recent Posts

Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones
Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities

Recent Comments

Archives

Categories

Portfolio News
TCG News

The Column Group

Copyright © 2022. The Column Group | Privacy Policy | Terms of Use
Website developed by CP Communications